Recent developments include capital raises to support CyPath Lung sales, ongoing clinical trials, and distribution agreements, alongside quarterly earnings reflecting mixed sales performance and net losses.

• In October 2026, bioAffinity priced a $4 million direct offering and added warrants to support CyPath Lung sales [N1].
• In May 2026, the company reported Q1 earnings with strength in CyPath Lung but stock slipped post-earnings [N2].
• In March 2026, bioAffinity launched a large-scale lung cancer clinical study enrolling high-risk patients [N3].
• In November 2025, Q3 earnings reflected lower sales and wider loss, causing stock to dip [N4].
• In August 2025, Q2 earnings showed CyPath Lung growth but overall stock declined [N5].
• In August 2025, the company missed Q2 revenue targets [N6].
• In May 2025, Q1 earnings showed revenue decline but stock rose post-earnings [N8].

The company has demonstrated clinical validation of its CyPath® Lung test with strong sensitivity and specificity metrics, supported by peer-reviewed studies and ongoing large-scale clinical trials. Its proprietary AI-driven diagnostic platform addresses a critical need in lung cancer detection, potentially improving patient outcomes and reducing healthcare costs. Recent capital raises and distribution agreements provide resources to support commercialization efforts. Expansion into companion diagnostics for asthma and COPD and novel cancer therapeutics could diversify future revenue streams. The company's CAP-accredited laboratory infrastructure supports quality and scalability.

The company operates at a net loss with limited revenue and substantial accumulated deficits, raising concerns about its ability to sustain operations without additional capital. Its business depends on successful development, regulatory approval, and commercialization of diagnostic tests and therapeutics, which are in preliminary stages and subject to significant uncertainties. The company faces operational challenges in scaling laboratory services and relocating research facilities. Market adoption risks, competitive pressures, and regulatory hurdles could impede growth. There is substantial doubt about the company's ability to continue as a going concern beyond March 2027 without further financing.

bioAffinity's moat lies in its proprietary CyPath® Lung diagnostic test that combines flow cytometry with machine learning AI to noninvasively detect early-stage lung cancer with high sensitivity and specificity. The test addresses a significant unmet need by improving diagnostic accuracy beyond standard low-dose CT screening, potentially reducing unnecessary invasive procedures and healthcare costs. The company's ownership of a CAP-accredited and CLIA-certified laboratory (PPLS) supports quality control and operational capability. Additionally, ongoing clinical trials and research collaborations with military and academic institutions enhance the scientific validation and potential adoption of its diagnostic platform. However, the moat is contingent on successful commercialization, regulatory approvals, and continued innovation in diagnostics and therapeutics.

• Capital and Liquidity Risk: The company relies heavily on raising additional capital to fund operations and development. Insufficient financing could force curtailment or cessation of operations.
• Early Stage Development Risk: Diagnostic tests and therapeutic products are in preliminary phases, requiring successful clinical trials, regulatory approvals, and commercialization efforts that may not materialize.
• Regulatory Approval Risk: Obtaining necessary regulatory clearances for diagnostic tests and therapeutics is uncertain and could delay or prevent market entry.
• Operational and Scaling Risk: Challenges include managing laboratory operations, relocating research facilities, and accurately estimating expenses, which could impact financial performance.

• bioAffinity Technologies, Inc. develops noninvasive diagnostic laboratory tests for early-stage lung cancer and other lung diseases using flow cytometry combined with machine learning AI.
• Their first commercial diagnostic test, CyPath® Lung, detects cancer and cancer-related cells in sputum to identify lung malignancies, particularly early-stage lung cancer (Stage 1A).
• CyPath® Lung is performed by their wholly owned subsidiary PPLS, a CAP-accredited and CLIA-certified clinical laboratory with over 18 years of operation.
• Clinical trials showed CyPath® Lung has 92% sensitivity, 87% specificity, and 88% accuracy for lung nodules less than 20 mm, with an AUC of 0.94 in this subset.
• CyPath® Lung aims to improve the positive predictive value of low-dose CT lung cancer screening, potentially reducing unnecessary invasive procedures and healthcare costs.
• The company is advancing companion diagnostic tests for asthma and COPD using their flow cytometry+AI platform to guide personalized treatment.
• They conduct research on novel cancer therapeutics targeting cancer cells selectively, with ongoing development for topical treatment of squamous cell skin cancer.
• Research and optimization occur at PPLS labs and leased space at UTSA, with plans to relocate research operations due to lease non-renewal.
• Financial snapshot as of 2026-09-30 shows cash and equivalents of $2.55 million, current assets of $3.83 million, current liabilities of $2.53 million, current ratio of 1.51, and cash ratio of 1.01.
• For the nine months ended September 30, 2026, revenue was approximately $3.9 million; for the year ended December 31, 2025, revenue was $6.2 million.
• Net loss for the nine months ended September 30, 2026 was approximately $5.28 million, with basic and diluted EPS of -$5.89 per share.
• The company has raised capital through multiple equity offerings totaling millions of dollars in recent years to fund operations and development.
• They have initiated a large-scale longitudinal clinical trial enrolling high-risk patients with indeterminate pulmonary nodules to validate CyPath Lung's clinical performance.
• The company maintains CAP accreditation for PPLS laboratory services, indicating adherence to high standards of quality and patient safety.
• Recent developments include a $4 million direct offering with warrants to support CyPath Lung sales and a nationwide federal distribution agreement for CyPath Lung.
• The company faces substantial doubt about its ability to continue as a going concern beyond March 2027 without additional capital.
• Key risks include reliance on raising additional capital, the preliminary stage of product development and commercialization, regulatory approval uncertainties, and operational challenges in scaling laboratory services.